Background and objective: Long term young adult cancer survivors (YACS) can face serious life-threatening complications in multiple organ systems, and these may become more clinically significant with aging. However, there have been limited attempts to understand the risk of late-effects in this group. Therefore, this thesis aimed: to measure the overall and cause-specific risks of late effects among YACS, including late mortality, SMN and late morbidity leading to hospitalization; to identify the characteristics influence these risks; and to examine YACS’ willingness in participating late effects studies in the future. Methods: The first three studies used data collected from Childhood Adolescent and Young Adult Cancer Survivor (CAYACS)...
Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scar...
Despite an aggregate 5-year survival of 85%, many adolescents and young adults (AYAs, 15–39 years ol...
Purpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are ...
Background and objective: Long term young adult cancer survivors (YACS) can face serious life-threat...
Risk factors associated with late effects in survivors of adolescent and young adult (AYA) cancer ar...
Purpose: Survival from childhood, teenage, and young adult cancer has increased substantially, with ...
Copyright © 2012 Yang Zhang et al. This is an open access article distributed under the Creative Com...
Significant advancements in the treatment of childhood cancers have helped to increase the 5-year su...
Purpose: We sought to identify factors, other than cancer-related treatment and presence/severity of...
Purpose - To investigate lifestyle in a population-based sample of long-term (≥ 5 years since diagno...
Within this chapter, we begin with the invaluable context of the experience of living after cancer a...
Thesis (Master's)--University of Washington, 2018Background: Young adult (YA) cancer survivors face ...
INTRODUCTION:The number of cancer survivors is projected to increase to 22.1 million by 2030. Late e...
BackgroundKnowledge regarding late effects (medical conditions and subsequent neoplasms) in survivor...
The number of cancer survivors is increasing. Knowledge gaps exist regarding the health of survivors...
Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scar...
Despite an aggregate 5-year survival of 85%, many adolescents and young adults (AYAs, 15–39 years ol...
Purpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are ...
Background and objective: Long term young adult cancer survivors (YACS) can face serious life-threat...
Risk factors associated with late effects in survivors of adolescent and young adult (AYA) cancer ar...
Purpose: Survival from childhood, teenage, and young adult cancer has increased substantially, with ...
Copyright © 2012 Yang Zhang et al. This is an open access article distributed under the Creative Com...
Significant advancements in the treatment of childhood cancers have helped to increase the 5-year su...
Purpose: We sought to identify factors, other than cancer-related treatment and presence/severity of...
Purpose - To investigate lifestyle in a population-based sample of long-term (≥ 5 years since diagno...
Within this chapter, we begin with the invaluable context of the experience of living after cancer a...
Thesis (Master's)--University of Washington, 2018Background: Young adult (YA) cancer survivors face ...
INTRODUCTION:The number of cancer survivors is projected to increase to 22.1 million by 2030. Late e...
BackgroundKnowledge regarding late effects (medical conditions and subsequent neoplasms) in survivor...
The number of cancer survivors is increasing. Knowledge gaps exist regarding the health of survivors...
Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scar...
Despite an aggregate 5-year survival of 85%, many adolescents and young adults (AYAs, 15–39 years ol...
Purpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are ...